Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy

Almeida, C; Mendes, R; Pezzarossa, A; Gago, J; Carvalho, C; Alves, A, et al.

http://hdl.handle.net/10400.10/2410

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Communications Biology.pdf		10.22 MB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

Cancer is the second leading cause of death in the world. Given that cancer is a highly individualized disease, predicting the best chemotherapeutic treatment for individual patients can be difficult. Ex vivo models such as mouse patient-derived xenografts (PDX) and organoids are being developed to predict patient-specific chemosensitivity profiles before treatment in the clinic. Although promising, these models have significant disadvantages including long growth times that introduce genetic and epigenetic changes to the tumor. The zebrafish xenograft assay is ideal for personalized medicine. Imaging of the small, transparent fry is unparalleled among vertebrate organisms. In addition, the speed (5-7 days) and small patient tissue requirements (100-200 cells per animal) are unique features of the zebrafish xenograft model that enable patient-specific chemosensitivity analyses.

Keywords

Zebrafish Bevacizumab Cancer therapy

URI

http://hdl.handle.net/10400.10/2410

Citation

Commun Biol. 2020 Jun 10;3(1):299

Publisher

Nature Publishing Group UK

DOI

10.1038/s42003-020-1015-0

Collections

ANPAT - Artigos publicados em revistas não indexadas

Altmetrics

Full item page